Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Tyde Wellness vs YourHealthRx

By GLP-1 ScorecardUpdated

Tyde Wellness
Site position #40

Higher grade

YourHealthRx
Site position #135

Lower grade

Score comparison

Tyde Wellness has the higher recorded score — 79.8/100 to 69.6/100.

Tyde Wellness grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Tyde Wellness is a 50-state compounded-GLP-1 and longevity telehealth platform spanning weight loss, HRT, hair, and peptides.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueTyde Wellness +33
86
53
Dose & formulationTyde Wellness +8
83
75
Clinical oversightTyde Wellness +2
89
87
Labs & monitoringYourHealthRx +13
54
67
FulfillmentYourHealthRx +3
91
94
Contract termsTyde Wellness +28
61
33
Tyde Wellness · top barYourHealthRx · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricTyde WellnessYourHealthRx
WeighScore79.8/10069.6/100
GradeC+C
Site position#40#135
Semaglutide$149/mo (microdose tier, all doses, compounded)$170/mo (compounded)
Tirzepatide$249/mo (microdose tier, all doses, compounded)$210/mo (compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessNot confirmedNot confirmed
Oral / sublingualYesYes
Tyde Wellness

Site position #40 · C+

Strengths

  • All 50 states served (full list published)
  • Transparent pricing: semaglutide from $149/mo, tirzepatide from $249/mo
  • LegitScript Certified with a verification link
  • Five named 503A pharmacy partners with addresses: Belmar (CO), Casa (TX), Olympia (FL), Red Rock (UT), Beaker (TX)
  • Free consultation; cancel-anytime subscription with no long-term commitment

What to consider

  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
  • No brand-name GLP-1s (Wegovy, Zepbound, Mounjaro, Ozempic)
  • Tirzepatide priced higher than competitors offering $200-$249/mo
  • Corporate address and medical director not publicly disclosed
  • No NABP.pharmacy seal visible
YourHealthRx

Site position #135 · C

Strengths

  • Available in all 50 states and DC through a multi-state (IMLC) licensed clinician network
  • Compounded semaglutide and tirzepatide in two formats - weekly injectable (with B12) or daily oral dissolving tablet
  • Flat subscription price that doesn't change as your dose increases (no titration penalty)
  • Science-forward, clinician-led, with built-in follow-up, lab testing, and a broad peptide and longevity catalog (BPC-157, TB-500, sermorelin, NAD+)
  • Transparent, education-first positioning with published medical disclaimer, privacy, and terms

What to consider

  • Eligibility and prescribing run through partner clinical workflows - YourHealthRx is the platform, not the prescriber or pharmacy
  • Compounded medications are not FDA-approved - not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • The compounding pharmacy partner is not named ('transparent sourcing' claimed but no pharmacy disclosed)
  • Headline prices include a first-month intro rate; ongoing monthly cost is higher (semaglutide ~$170, tirzepatide ~$210)
  • No LegitScript certification displayed

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard